TOKYO, July 13, 2021 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for 10 consecutive years, as a company that is performing excellent initiatives in the areas of ESG [environmental (E), social (S), governance (G)].
Astellas has conducted various activities based on the thought that Astellas’ contribution to the sustainability of society means the realization its philosophy. These sustained activities led Astellas to recognize and to be selected in such for a decade.
In the year ended 31 March 2021, Astellas reviewed its past activities and formulated its basic sustainability policy, which aims to improve the sustainability of both the global society and Astellas with the ESG in mind, instead of the conventional CSR-Based management. Astellas is working to further conducte its sustainability activities and expand its information disclosure*1.
Astellas has set "Deepen our Engagement in Sustainability" as one of its new strategic goals in its Corporate Strategic Plan 2021*2. In addition to implementing "Value Protection" which is an initiative to comply with regulations and meet the requirements from the global society, Astellas will further strengthen "Value Creation" activities to provide its patients’ access to innovative therapeutics and take proactive measures to conserve the global environment.
Besides the FTSE4Good Index Series, Astellas also has been named to all ESG investment indices selected by the Government Pension Investment Fund of Japan. These are the FTSE Blossom Japan Index, the MSCI Japan ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN), and the S&P/JPX Carbon Efficient Index.
Astellas will continue to work under its basic policy of sustainability, which is to improve the sustainability of both the global society and Astellas while keeping ESG in mind.
Click below for a copy of the full press release